BioSpace News Archive

BioInvent International AB (“BioInvent”) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today present new data on BT-001,

– Data from melanoma and SCCHN cohorts demonstrate eganelisib was well tolerated in combination with Opdivo ® – - Translational data supports on-mechanism immune modulation - - Clinical activity in patients with two or fewer prior lines of therapy validates Infinity’s clinical strategy advancing eganelisib to earlier treatment settings –

Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management and supply chain solutions for health systems, today announced a new partnership with Allegheny Health Network (AHN), to provide central pharmacy dispensing and medication management at the point of care across the network’s 13 hospital locations in western Pennsylvania.

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 6-month data from the AVESS first-in-human (FIH) study of the company’s Avess™ AV Fistula drug-coated balloon (DCB) was shared during a morning session at the Vascular Interventional Advances (VIVA) 2020 virtual conference.

Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing proprietary spherical nucleic acid (SNA™) technology, today announced the presentation of updated Phase 1b data from the ongoing Phase 1b/2 clinical trial evaluating intratumoral cavrotolimod

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that its abstract highlighting data from Part B of the ongoing Phase 1/2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (GBM) was accepted for e-poster presentation at the 25 th Annual Meet

Masimo announced that its Founder, Chairman, and CEO, Joe Kiani, has been honored by the Ibero-American Society of Neonatology at its 17th Annual Congress with the Award for Improvement of Neonatal Health in Latin America.

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, November 17, 2020 to discuss the Company’s financial results for the fiscal 2021 second quarter ended September 30, 2020, as well as the Company’s corporate progress and other developments.

IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that the peer-reviewed journal, International Journal of Clinical Pharmacy, has published a study on Montelukast’s effect on neurological aging

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced the completion of enrollment in the ongoing Phase 2 clinical trial of EB613. EB613 is an orally delivered human parathyroid hormone (1-34), or PTH, positioned as the first potential oral bone building product to treat osteoporosis patients.